From genes to therapy: navigating the complex landscape of neurofibromatosis management in Canada through advanced diagnostic, targeted therapies, and holistic care.

Neurofibromatosis (NF) presents a significant clinical challenge due to its complex genetic basis, diverse clinical manifestation, and substantial impact on a patient's quality of life (QoL). This paper explores the multifaceted approach required to manage NF in Canada, emphasizing the integration of advanced diagnostic tools, targeted treatments, and comprehensive support systems. Healthcare providers, researchers, patient advocacy groups, and policymakers must collaborate to ensure NF patients receive the best possible care and support. This disease poses devastating consequences to families, and there has been a lack of awareness of this issue in Vancouver and, generally, in British Columbia. Currently, there is no clinic dedicated explicitly to NF in Metro Vancouver, and patients diagnosed with this disease must be flown to Toronto to get treated. The process is costly and inefficient, demanding changes. Some recent improvements in the field of NF have been noted, such as the use of gene therapy and MEK inhibitors. However, the long-term effect of this treatment is largely unknown and should be viewed with caution. This underscores the importance of enhancing psychological interventions to address the mental health challenges faced by NF patients. Specific gene sequences for different types of NF have also been mentioned in the article to offer insights on potential targets for gene-editing technology like CRISPR. Through ongoing advancements in medical science and a commitment to patient-centered care, this paper envisions significant improvements in the management and treatment of this complex condition.